Inactivation of ERCC5 has been shown to result in increased sensitivity to cisplatin in a variety of cancers, including non-small cell lung cancer, epithelial ovarian cancer, and uroepithelial cancer [27–29]. The gene discussed is ERCC5; the disease is cancer.